Cargando…
Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases
BACKGROUND: Benralizumab, a humanized, afucosylated, monoclonal antibody that targets interleukin-5 receptor α, depletes eosinophils and basophils by enhanced antibody-dependent cell-mediated cytotoxicity. It demonstrated efficacy for patients with moderate to severe asthma and, in a Phase IIa trial...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339432/ https://www.ncbi.nlm.nih.gov/pubmed/30658649 http://dx.doi.org/10.1186/s12931-018-0968-8 |
_version_ | 1783388637837131776 |
---|---|
author | Sridhar, Sriram Liu, Hao Pham, Tuyet-Hang Damera, Gautam Newbold, Paul |
author_facet | Sridhar, Sriram Liu, Hao Pham, Tuyet-Hang Damera, Gautam Newbold, Paul |
author_sort | Sridhar, Sriram |
collection | PubMed |
description | BACKGROUND: Benralizumab, a humanized, afucosylated, monoclonal antibody that targets interleukin-5 receptor α, depletes eosinophils and basophils by enhanced antibody-dependent cell-mediated cytotoxicity. It demonstrated efficacy for patients with moderate to severe asthma and, in a Phase IIa trial, for chronic obstructive pulmonary disease (COPD) with eosinophilic inflammation. We investigated effects of benralizumab 100 mg every 8 weeks (first three doses every 4 weeks) subcutaneous on blood inflammatory markers through proteomic and gene-expression analyses collected during two Phase II studies of patients with eosinophilic asthma and eosinophilic COPD. METHODS: Serum samples for proteomic analysis and whole blood for gene expression analysis were collected at baseline and 52 weeks (asthma study) or 32 weeks (COPD study) post-treatment. Proteomic analyses were conducted on a custom set of 90 and 147 Rules-Based Medicine analytes for asthma and COPD, respectively. Gene expression was profiled by Affymetrix Human Genome U133 plus 2 arrays (~ 54 K probes). Gene set variation analysis (GSVA) was used to determine transcriptomic activity of immune signatures. Treatment-related differences between analytes, genes, and gene signatures were analyzed for the overall population and for patient subgroups stratified by baseline blood eosinophil count (eosinophil-high [≥300 cells/μL] and eosinophil-low [< 300 cells/μL]) via t-test and repeated measures analysis of variance. RESULTS: Eosinophil chemokines eotaxin-1 and eotaxin-2 were significantly upregulated (false discovery rate [FDR] < 0.05) by approximately 2.1- and 1.4-fold in the asthma study and by 2.3- and 1.7-fold in the COPD study following benralizumab treatment. Magnitude of upregulation of these two chemokines was greater for eosinophil-high patients than eosinophil-low patients in both studies. Benralizumab was associated with significant reductions (FDR < 0.05) in expression of genes associated with eosinophils and basophils, such as CLC, IL-5Rα, and PRSS33; immune-signaling complex genes (FCER1A); G-protein–coupled receptor genes (HRH4, ADORA3, P2RY14); and further immune-related genes (ALOX15 and OLIG2). The magnitude of downregulation of gene expression was greater for eosinophil-high than eosinophil-low patients. GSVA on immune signatures indicated significant treatment reductions (FDR < 0.05) in eosinophil-associated signatures. CONCLUSIONS: Benralizumab is highly selective, modulating blood proteins or genes associated with eosinophils or basophils. Modulated protein and gene expression patterns are most prominently altered in eosinophil-high vs. eosinophil-low patients. TRIAL REGISTRATION: NCT01227278 and NCT01238861. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12931-018-0968-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6339432 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63394322019-01-23 Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases Sridhar, Sriram Liu, Hao Pham, Tuyet-Hang Damera, Gautam Newbold, Paul Respir Res Research BACKGROUND: Benralizumab, a humanized, afucosylated, monoclonal antibody that targets interleukin-5 receptor α, depletes eosinophils and basophils by enhanced antibody-dependent cell-mediated cytotoxicity. It demonstrated efficacy for patients with moderate to severe asthma and, in a Phase IIa trial, for chronic obstructive pulmonary disease (COPD) with eosinophilic inflammation. We investigated effects of benralizumab 100 mg every 8 weeks (first three doses every 4 weeks) subcutaneous on blood inflammatory markers through proteomic and gene-expression analyses collected during two Phase II studies of patients with eosinophilic asthma and eosinophilic COPD. METHODS: Serum samples for proteomic analysis and whole blood for gene expression analysis were collected at baseline and 52 weeks (asthma study) or 32 weeks (COPD study) post-treatment. Proteomic analyses were conducted on a custom set of 90 and 147 Rules-Based Medicine analytes for asthma and COPD, respectively. Gene expression was profiled by Affymetrix Human Genome U133 plus 2 arrays (~ 54 K probes). Gene set variation analysis (GSVA) was used to determine transcriptomic activity of immune signatures. Treatment-related differences between analytes, genes, and gene signatures were analyzed for the overall population and for patient subgroups stratified by baseline blood eosinophil count (eosinophil-high [≥300 cells/μL] and eosinophil-low [< 300 cells/μL]) via t-test and repeated measures analysis of variance. RESULTS: Eosinophil chemokines eotaxin-1 and eotaxin-2 were significantly upregulated (false discovery rate [FDR] < 0.05) by approximately 2.1- and 1.4-fold in the asthma study and by 2.3- and 1.7-fold in the COPD study following benralizumab treatment. Magnitude of upregulation of these two chemokines was greater for eosinophil-high patients than eosinophil-low patients in both studies. Benralizumab was associated with significant reductions (FDR < 0.05) in expression of genes associated with eosinophils and basophils, such as CLC, IL-5Rα, and PRSS33; immune-signaling complex genes (FCER1A); G-protein–coupled receptor genes (HRH4, ADORA3, P2RY14); and further immune-related genes (ALOX15 and OLIG2). The magnitude of downregulation of gene expression was greater for eosinophil-high than eosinophil-low patients. GSVA on immune signatures indicated significant treatment reductions (FDR < 0.05) in eosinophil-associated signatures. CONCLUSIONS: Benralizumab is highly selective, modulating blood proteins or genes associated with eosinophils or basophils. Modulated protein and gene expression patterns are most prominently altered in eosinophil-high vs. eosinophil-low patients. TRIAL REGISTRATION: NCT01227278 and NCT01238861. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12931-018-0968-8) contains supplementary material, which is available to authorized users. BioMed Central 2019-01-18 2019 /pmc/articles/PMC6339432/ /pubmed/30658649 http://dx.doi.org/10.1186/s12931-018-0968-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Sridhar, Sriram Liu, Hao Pham, Tuyet-Hang Damera, Gautam Newbold, Paul Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases |
title | Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases |
title_full | Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases |
title_fullStr | Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases |
title_full_unstemmed | Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases |
title_short | Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases |
title_sort | modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339432/ https://www.ncbi.nlm.nih.gov/pubmed/30658649 http://dx.doi.org/10.1186/s12931-018-0968-8 |
work_keys_str_mv | AT sridharsriram modulationofbloodinflammatorymarkersbybenralizumabinpatientswitheosinophilicairwaydiseases AT liuhao modulationofbloodinflammatorymarkersbybenralizumabinpatientswitheosinophilicairwaydiseases AT phamtuyethang modulationofbloodinflammatorymarkersbybenralizumabinpatientswitheosinophilicairwaydiseases AT dameragautam modulationofbloodinflammatorymarkersbybenralizumabinpatientswitheosinophilicairwaydiseases AT newboldpaul modulationofbloodinflammatorymarkersbybenralizumabinpatientswitheosinophilicairwaydiseases |